Dr. Reddy's Laboratories Limited (RDY) — Earnings Call X-Ray
Our AI read all 33 of RDY's earnings calls (2016–2025) and answered the same battery of questions about each one. Every past call is free; the newest quarter unlocks with a free account.
Previous Call Grade
C
Q4 2025
Calls Analyzed
33
2016–2025
Avg Candor
6.4/9
evasion 4.8/9
Call-by-call analysis
🔒 Q1 2026 earnings call
2025-07-23
NEWEST
Guidance: ■■■■■Demand: ■■■■■■
Margins: ■■■■Backlog: ■■■■
■ analysts, ■■ questionsexpected move ±■■%
Management ■■■■■■ guidance against ■■■■■■■■ demand and ■■■■■■■ margins. The delivery was ■■■■■■■■ and ■■■■ in specifics, with ■■■ questions left hanging.
🔒 The Q1 2026 call grade is ready
The full 37-point AI read of RDY's newest earnings call — grade, expected move, and every question answered — is free with an account.
Sign up free to unlock
C
Q4 2025 earnings call
2025-05-09
Management held guidance steady against steady demand. The delivery was rich in specifics.
Guidance: maintainedDemand: stableMargins: stablePricing: under pressureCapex: increasing 12 analysts · 26 questions
⚑ Critic ammunition✓ Skeptic reassured⚑ Question left hanging✓ Guidance underwritable✓ Resolves doubts✓ Volume step-up ahead
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
C+
Q3 2025 earnings call
2025-01-23
Management held guidance steady against steady demand and contracting margins. The delivery was unusually candid, rich in specifics.
Guidance: maintainedDemand: stableMargins: contractingPricing: under pressureCapex: increasing 12 analysts · 34 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts✓ Volume step-up ahead✓ Early product, fast growth
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
YES Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
C
Q2 2025 earnings call
2024-11-05
Management held guidance steady against accelerating demand. The delivery was rich in specifics.
Guidance: maintainedDemand: acceleratingMargins: stablePricing: under pressureCapex: increasing 12 analysts · 31 questions
⚑ Critic ammunition✓ Skeptic reassured⚑ Question left hanging✓ Guidance underwritable✓ Resolves doubts
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?
C
Q4 2024 earnings call
2024-05-07
Management gave no formal guidance against steady demand. The delivery was rich in specifics.
Demand: stableMargins: stablePricing: under pressureCapex: increasing 11 analysts · 30 questions
⚑ Critic ammunition✓ Skeptic reassured⚑ Question left hanging✓ Guidance underwritable✓ Resolves doubts⚑ Reads rehearsed
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
C
Q3 2024 earnings call
2024-01-30
Management held guidance steady against steady demand.
Guidance: maintainedDemand: stableMargins: stablePricing: under pressureCapex: flat 8 analysts · 30 questions
⚑ Critic ammunition✓ Skeptic reassured⚑ Question left hanging✓ Guidance underwritable✓ Resolves doubts⚑ Reads rehearsed
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
C+
Q2 2024 earnings call
2023-10-27
Management held guidance steady against steady demand. The delivery was unusually candid, rich in specifics.
Guidance: maintainedDemand: stableMargins: stablePricing: under pressureHeadcount: flatCapex: flat 10 analysts · 26 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?
C
Q1 2024 earnings call
2023-07-26
Management held guidance steady against accelerating demand and expanding margins. The delivery was unusually candid.
Guidance: maintainedDemand: acceleratingMargins: expandingPricing: stableCapex: flat 11 analysts · 29 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts✓ Volume step-up ahead✓ Early product, fast growth
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
YES Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
Earlier calls
| Call | Date | Grade | Guidance | Demand | Margins | Candor | Evasion |
|---|
| Q4 2023 |
2023-05-11 |
D |
maintained | stable | expanding |
5/9 |
5/9 |
| Q3 2023 |
2023-01-25 |
D |
maintained | accelerating | expanding |
5/9 |
6/9 |
| Q2 2023 |
2022-10-28 |
C |
maintained | accelerating | expanding |
6/9 |
4/9 |
| Q1 2023 |
2022-07-31 |
C+ |
maintained | mixed | contracting |
7/9 |
4/9 |
| Q4 2022 |
2022-05-19 |
C |
maintained | stable | stable |
6/9 |
5/9 |
| Q3 2022 |
2022-01-28 |
C |
maintained | stable | stable |
6/9 |
4/9 |
| Q1 2021 |
2021-07-27 |
D |
maintained | mixed | contracting |
7/9 |
4/9 |
| Q4 2021 |
2021-05-14 |
C |
maintained | mixed | stable |
6/9 |
4/9 |
| Q3 2021 |
2021-01-29 |
C+ |
maintained | mixed | stable |
7/9 |
3/9 |
| Q2 2021 |
2020-10-28 |
D |
maintained | accelerating | stable |
6/9 |
6/9 |
| Q1 2021 |
2020-07-30 |
B |
none | mixed | expanding |
7/9 |
4/9 |
| Q4 2020 |
2020-05-20 |
D |
none | mixed | stable |
6/9 |
6/9 |
| Q3 2020 |
2020-01-27 |
C |
none | accelerating | expanding |
6/9 |
5/9 |
| Q2 2020 |
2019-11-01 |
D |
none | mixed | contracting |
7/9 |
4/9 |
| Q4 2019 |
2019-05-17 |
D |
none | stable | stable |
6/9 |
5/9 |
| Q3 2019 |
2019-02-01 |
C |
maintained | stable | contracting |
7/9 |
6/9 |
| Q4 2018 |
2018-05-23 |
F |
maintained | mixed | contracting |
6/9 |
6/9 |
| Q3 2018 |
2018-01-25 |
F |
maintained | mixed | stable |
5/9 |
7/9 |
| Q2 2018 |
2017-10-31 |
F |
maintained | mixed | stable |
6/9 |
6/9 |
| Q1 2018 |
2017-07-27 |
F |
none | mixed | contracting |
7/9 |
5/9 |
| Q4 2017 |
2017-05-15 |
F |
none | mixed | contracting |
7/9 |
6/9 |
| Q2 2017 |
2016-10-25 |
F |
maintained | mixed | stable |
6/9 |
6/9 |
| Q2 2016 |
2016-07-27 |
F |
maintained | slowing | contracting |
7/9 |
6/9 |
| Q4 2016 |
2016-05-13 |
D |
maintained | mixed | contracting |
7/9 |
4/9 |
| Q3 2016 |
2016-02-09 |
F |
lowered | mixed | expanding |
7/9 |
6/9 |
How to read this page
The grade is a transparent composite of call quality — candor, specificity, low evasion, low stress, whether the call resolves more doubts than it creates, and the guidance action — not a buy or sell signal. The expected move is a volatility estimate from the one signal that survived our out-of-sample tests: how a stock's own reaction and pre-call volatility predict the size (not direction) of its next move. Full detail, including everything that failed: methodology.
Companies with similar call quality
← RDWR All “R” companies
RE →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our
methodology.